Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

Overview of attention for article published in Journal of Hematology & Oncology, September 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

So far, Altmetric has seen 6 patents that reference this research output.

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 2 additional patents.